Qual é o preço para Chinook Therapeutics, Inc. (KDNY)

O preço para Chinook Therapeutics, Inc. (KDNY) é $40.39

Qual é a capitalização de mercado para Chinook Therapeutics, Inc. (KDNY)

A capitalização de mercado para Chinook Therapeutics, Inc. (KDNY) é $1.70B

Histórico de Preços de Chinook Therapeutics, Inc. (KDNY)

Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Ano	Desempenho
2023	63.66%
2022	55.54%
2021	0.37%
2020	175.05%
2019	-57.15%
2018	-67.16%
2017	-26.51%
2016	-62.61%
2015	0.00%

Ano

Desempenho

2023

63.66%

2022

55.54%

2021

0.37%

2020

175.05%

2019

-57.15%

2018

-67.16%

2017

-26.51%

2016

-62.61%

2015

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$548.36	39.87%	US
Argenx SE ARGX.US	$1.06K	50.29%	NL
CSL Limited CSL.AX	$121.53	-12.48%	AU
Moderna, Inc. MRNA.US	$140.81	475.44%	US
Lonza Group AG LONN.SW	$765.25	7.74%	CH

Empresa

Preço da ação

Variação 1a%

País